Olema Pharmaceuticals, Inc. (OLMA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Company Overview - Olema aims to improve treatments for patients with ER-positive HER2-negative breast cancer, addressing significant unmet needs in this common cancer indication [1] Clinical Programs - Olema has two programs in the clinic: one in Phase III trials and one in Phase I/Phase Ib [2] - The lead asset, palazestrant, is a complete estrogen receptor antagonist, which is believed to be the best endocrine therapy for ER-positive HER2-negative breast cancer [2] Treatment Approach - Endocrine therapy is the backbone of treatment for ER-positive HER2-negative breast cancer, as the estrogen receptor is a primary driver of tumor growth and proliferation [3] - Palazestrant is currently in a first-line trial in combination with ribociclib, marking it as the only first-line trial of a CERAN/SERD in the endocrine-sensitive wild-type ESR1 setting [3] - Additionally, palazestrant is involved in a second third-line trial, OPERA-01, as a monotherapy [3]